| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
| US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
| US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
| US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
| US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) | |
Simcor is owned by Abbvie.
Simcor contains Niacin; Simvastatin.
Simcor has a total of 9 drug patents out of which 9 drug patents have expired.
Expired drug patents of Simcor are:
- US7011848
- US6406715
- US6129930
- US6676967
- US7998506
- US6746691
- US6818229
- US6080428
- US6469035
Simcor was authorised for market use on 15 February, 2008.
Simcor is available in tablet, extended release;oral dosage forms.
Simcor can be used as adjunct to diet to reduce elevated total-c, ldl-c, non-hdl-c, apo b, tg, and lp(a) levels and to increase hdl-c in patients with primary hypercholesterolemia, mixed dyslipidemia, and hypertriglyceridemia, treatment of hypertriglyceridemia by dosing once per day in the evening or at night, with pretreatment with a flush inhibiting agent such as aspirin, treatment of hypercholesterolemia by dosing once per day in the evening or at night, through reduction in total-c, ldl-c, tg, lp(a), and increase of hdl-c.
The generics of Simcor are possible to be released after 15 March, 2018.
Drugs and Companies using NIACIN; SIMVASTATIN ingredient
Market Authorisation Date: 15 February, 2008
Treatment: Adjunct to diet to reduce elevated total-c, ldl-c, non-hdl-c, apo b, tg, and lp(a) levels and to increase hdl-c in patients with primary hypercholesterolemia, mixed dyslipidemia, and hypertriglyceride...
Dosage: TABLET, EXTENDED RELEASE;ORAL
SIMCOR family patents
